Opis działalności
Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncolog.
Their lead candidate, RVU120, is a selective CDK8/CDK19 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors. SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, in Phase 2 clinical development for the treatment of acute myeloid leukemia.
Zarząd & Rada nadzorcza
| CEO |
| Paweł Przewięźlikowski |
| Zarząd |
| Vatnak Vat-Ho, Hendrik Nogai, Kamil Sitarz, Krzysztof Brzózka |
| Rada nadzorcza |
| Piotr Romanowski, Tadeusz Wesołowski, Rafał Chwast, Axel Glasmacher, Jarl Jungnelius, Thomas Turalski |
Dane firmy
| Nazwa: |
RYVU THERAPEUTICS S.A. |
| Adres: |
Leona Henryka Sternbacha 2,30-394 Kraków |
| Telefon: |
+48 12 314 02 00 |
| Fax: |
+48 12 297 47 01 |
| E-mail: |
ryvu@ryvu.com
|
| Internet: |
https://ryvu.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
- |
| Koniec roku finansowego: |
31.12 |
| Free float: |
74,30% |
| Data IPO: |
14.07.2011 |
Relacje inwestorskie
| Nazwa: |
- |
| Telefon: |
- |
| Fax: |
- |
| E-mail: |
ir@ryvu.com
|
